GT Biopharma Inc. Common Stock (GTBP) is a publicly traded Healthcare sector company. As of September 15, 2026, GTBP trades at $8.96 with a market cap of $15.54M and a P/E ratio of -1.70. GTBP moved -25.37% today. Year to date, GTBP is -40.75%; over the trailing twelve months it is -42.21%. Its 52-week range spans $4.91 to $96.25. Analyst consensus is moderatebuy with an average price target of $3.00. Rallies surfaces GTBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GT Biopharma Inc. Common Stock (GTBP) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. GTBP moved -25.37% today. Analyst consensus is moderatebuy.
| Metric | Value |
|---|---|
| Price | $8.96 |
| Market Cap | $15.54M |
| P/E Ratio | -1.70 |
| EPS | $-6.68 |
| Dividend Yield | 0.00% |
| 52-Week High | $96.25 |
| 52-Week Low | $4.91 |
| Volume | 187.02K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-28.35M |
| Gross Margin | 0.00% |
1 analysts cover GTBP: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is moderatebuy. Average price target: $3.00.